Payment overview · 2025
General Payments
$902.54
58 reported records · 17 companies
Healthcare provider profile · identity verified
William B Buselmeier, MD
Allopathic & Osteopathic Physicians|Family Medicine · JOHNSON CITY, TN · NPI 1548608375
Verified facts
What the public records show
CMS Open Payments records show William B Buselmeier, MD received $902.54 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $199.42 | 22.1% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $158.52 | 17.6% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $137.89 | 15.3% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.85 | 7.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.48 | 5.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.19 | 5.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.50 | 5.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.71 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.24 | 2.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.89 | 2.5% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $19.61 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.68 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 2.0% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.83 | 1.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.06 | 1.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.12 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $902.54 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.28 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $89.73 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $84.80 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.56 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.56 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $49.48 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.16 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.16 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.50 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $44.06 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.12 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $3.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 205 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 490 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 139 |
| Lisinopril | Lisinopril | 369 | 145 |
| Atorvastatin Calcium | Atorvastatin Calcium | 336 | 128 |
| Losartan Potassium | Losartan Potassium | 305 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 288 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 85 |
| Omeprazole | Omeprazole | 218 | 80 |
| Eliquis | Apixaban | 205 | 43 |
| Gabapentin | Gabapentin | 150 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 57 |
| Meloxicam | Meloxicam | 127 | 47 |
| Metformin Hcl | Metformin Hcl | 118 | 48 |
| Metformin Hcl Er | Metformin Hcl | 118 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 45 |
| Potassium Chloride | Potassium Chloride | 101 | 42 |
| Furosemide | Furosemide | 98 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 37 |
| Sertraline Hcl | Sertraline Hcl | 95 | 37 |
| Prednisone | Prednisone | 88 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 31 |
| Famotidine | Famotidine | 87 | 25 |
| Allopurinol | Allopurinol | 83 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 26 |
| Atenolol | Atenolol | 60 | 20 |
| Ozempic | Semaglutide | 59 | suppressed |
| Xarelto | Rivaroxaban | 59 | 13 |
| Tramadol Hcl | Tramadol Hcl | 56 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Montelukast Sodium | Montelukast Sodium | 51 | 20 |
| Trazodone Hcl | Trazodone Hcl | 51 | 21 |
| Alprazolam | Alprazolam | 50 | 13 |
| Carvedilol | Carvedilol | 46 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 26 |
| Alendronate Sodium | Alendronate Sodium | 43 | 20 |
| Ezetimibe | Ezetimibe | 43 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 42 | 25 |
| Spironolactone | Spironolactone | 41 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 13 |
| Farxiga | Dapagliflozin Propanediol | 40 | 11 |
| Glipizide | Glipizide | 38 | 14 |
| Ondansetron Odt | Ondansetron | 38 | 20 |
| Finasteride | Finasteride | 37 | 16 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | 15 |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 13 |
| Clonazepam | Clonazepam | 32 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | 12 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | 12 |
| Fluconazole | Fluconazole | 26 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | 11 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | 13 |
| Simvastatin | Simvastatin | 25 | 12 |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | 12 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | 11 |
| Valacyclovir | Valacyclovir Hcl | 22 | 13 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Celecoxib | Celecoxib | 19 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $902.54 · 58 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, Heplisav-B, JARDIANCE, KRYSTEXXA, NEXLETOL, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, VYEPTI, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error